Powell delivers early fireworks to markets Powell delivers early fireworks to markets Powell delivers early fireworks to markets

Powell delivers early fireworks to markets

Equities 4 minutes to read
Peter Garnry

Head of Saxo Strats

Summary:  Yesterday's US inflation report did nothing to stop the strong sentiment in equities setting markets up for a potential disappointment at tonight's FOMC press conference. US core services inflation has accelerated the past three months which might have spooked the Fed into doubling down on its message of higher for longer. If this is the case then equities will be great disappointed. After the US market close, Adobe will report earnings and investors are likely demanding that the company's generative AI product Firefly begin to move the needle on growth. If not, then it will be increasingly difficult to justify the current valuation.


The Fed buys into market narrative

Last night the FOMC bought into the recent market narrative pricing in rate cuts next year as inflation continues to cool, although in the short term US core services inflation remains high, forecasting three rate cuts next year compared to five cuts priced by the market (see price chart of SOFR Dec 2024 below). The message extended the rally in equities pushing Nasdaq 100 futures to a new all-time high on the close and the move has extended today with the index futures trading around the 16,850 level. It is not unrealistic to think that the S&P 500 could hit 5,000 in a complete melt-up scenario by yearend.

From a strategic perspective the Fed is happy with its policy forecast spread to market pricing on rate cuts as any error will force the market to correct first creating a buffer for policymakers. As such the Fed will likely continue to update its forecasts for rate cuts in tandem with market pricing keeping a certain spread in place with two rate cuts being the current spread. Some say that the market is getting too aggressive in its pricing but history is on the side of markets because when a rate cycle begins the policy rate trajectory often accelerates faster than most anticipate. This could easily happen again.

The logical narrative in the market is that the policy rate repricing drives the market through valuation expansion, but as our chart below shows there has been little logical connection between the market’s pricing of Fed policy rate Dec 2024 and the forward equity valuation of the S&P 500. In other words, if the repricing matters for equities is a local phenomenon and not a generalized dynamic. As we have been writing for quite some time, the market’s logic is this. As long as the policy rate is only projected to fall less than 200 bps then the interpretation is a soft landing meaning lowering discount rate on cash flow with stable nominal growth of 4-6%. This will support the positive momentum in equities, but if the policy rate pricing exceed the 200 bps then the equity market will begin realising that policy rate cuts are suddenly an expression of an incoming recession and then the market dynamic will flip upside down.

SOFR Dec 2024 futures | Source: Saxo
Nasdaq 100 futures | Source: Saxo

ECB cools market pricing on rate cuts

Today’s ECB rate decision was no surprise in the sense of policy rates remaining unchanged but the central bank reiterated its higher for longer message despite lowering its inflation forecasts for next year on core inflation to 2.7% from previously 2.9% in addition to lowering its Eurozone GDP forecast for 2024 to 0.8% from previously 1%. These new forecasts underscore the fragility of the Eurozone economy but also supports rate cuts next year although the market is today lowering the change in policy rate a bit. However, if the economy continues to be slow paced the market will likely resume its pricing of more aggressive rate cuts for next year. The current ECB policy rate pricing in Dec 2024 is 2.36% vs 4% deposit facility rate.

Pfizer shares are down 45% in 2023 as 2024 outlook disappoints

A terrible year for Pfizer got worse yesterday with shares falling another 7% extending this year’s decline to 45.6% as the company updated the market on its 2024 outlook. Pfizer is guiding revenue of $58.5-61.5bn vs est. $62.9bn. In addition, the company said it expects $4bn in cost savings next year, but the market was clearly weighing growth over profitability in the update. Pfizer’s lower market value has pushed its equity valuation to around 6.2% on the FY24 free cash flow yield and 7x on FY24 EV/EBITDA which is a significant discount to the S&P 500 which valued at 12x on EV/EBITDA. In that sense, Pfizer is now truly a value company, but it has likely also become the case for the patient investor as there are no near-term catalysts that can change sentiment except for falling bond yields.

Pfizer share price | Source: Saxo

Disclaimer

The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website. This content is not intended to and does not change or expand on the execution-only service. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-gb/legal/disclaimer/saxo-disclaimer)

Saxo Markets
40 Bank Street, 26th floor
E14 5DA
London
United Kingdom

Contact Saxo

Select region

United Kingdom
United Kingdom

Trade Responsibly
All trading carries risk. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more
Additional Key Information Documents are available in our trading platform.

Saxo Markets is a registered Trading Name of Saxo Capital Markets UK Ltd (‘SCML’). SCML is authorised and regulated by the Financial Conduct Authority, Firm Reference Number 551422. Registered address: 26th Floor, 40 Bank Street, Canary Wharf, London E14 5DA. Company number 7413871. Registered in England & Wales.

This website, including the information and materials contained in it, are not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in the United States, Belgium or any other jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation.

It is important that you understand that with investments, your capital is at risk. Past performance is not a guide to future performance. It is your responsibility to ensure that you make an informed decision about whether or not to invest with us. If you are still unsure if investing is right for you, please seek independent advice. Saxo Markets assumes no liability for any loss sustained from trading in accordance with a recommendation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Android is a trademark of Google Inc.

©   since 1992